Wall Street analyst estimates for Artelo Biosciences, Inc. (ARTL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |
Valuation Ratios
| Price / Book | 0.23 |
| EV / EBITDA | 0.15 |
| Dividend Yield | 0.00% |
Price
| Price | $3.75 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CARM · GTBP · LIPO · PBM · PTIX · REVB · SLRX
Explore sector: Healthcare · Biotechnology
More sections of ARTL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks